MAP Pharma Files for IPO

MAP Pharmaceuticals Inc., a Mountain View, Calif.-based developer of inhaled drug products for respiratory and CNS diseases, filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol MAPP, with Merrill Lynch and Morgan Stanley serving as co-lead underwriters. The company has raised around $107 million in total VC funding since its 2003 formation, including a $50 million Series D round earlier this year. Shareholders include Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital, Skyline Ventures and D.W. Shaw Group.